Life Technologies Japan Completes Installation of Japan National Police Agency's 3B Yen Investment to Upgrade Forensic Testing Instrumentation

TOKYO, Japan – March 25, 2010 – Life Technologies Japan, a subsidiary of Life Technologies Corporation (NASDAQ: LIFE), a provider of innovative life science solutions, today announced that it has completed the installation of DNA analysis software, genetic analyzers, and DNA extraction instrumentation for the National Police Agency (NPA) and its 47 prefectural forensic science laboratories. This installation represents a 3 billion yen (approximately $30M) investment by the NPA to modernize its testing systems in all prefectural police agencies across Japan, and increases their current capabilities to enable high throughput forensic testing. NPA chose Life Technologies’ forensic testing instrumentation because it meets the rigorous requirements to provide the highest quality testing results to law enforcement officers.

“Japan’s recent investment demonstrates a strong commitment to protecting public safety and establishes Japan’s prefectural forensic science laboratories as one of the world’s most sophisticated laboratory systems,” said Leonard Klevan, Ph.D., President of Human Identification at Life Technologies. “This commitment is part of a larger trend in the United States, Europe, China and other countries to utilize the power of DNA databases to share investigative information in order to enhance the criminal process and bring justice to victims worldwide.”

Japan transitioned to a mixed jury system for serious crimes in 2009. This change in the legal system created a need to evaluate a broader scope of evidence and is expected to increase the overall use of DNA in the investigative and legal process. “We expect that the enhanced capacity will accommodate this increasing need for more DNA analysis,” said Siddhartha Kadia, PhD., Chief Operating Officer of Life Technologies Japan. “Life Technologies has been providing leading edge DNA analysis instrumentations for Japan’s police system since the 1990’s. We are committed to ensuring that the latest instrumentation is utilized effectively to provide the highest quality testing results to law enforcement officers. We value the trust that the NRIPS and NPA have in Life Technologies, and will provide our best support as Japan transitions into a new legal system.”

About Life Technologies (www.lifetechnologies.com)

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

About Life Technologies Japan (http://www.lifetech.co.jp/)

Life Technologies Japan is a subsidiary of Life Technologies Corporation. Life Technologies brands are found in more than 90 percent of research laboratories in Japan. The company serves more than 55,000 end-users in Japan, including leading scientists in both academic and commercial life science and biotechnology organizations. Life Technologies Japan employs approximately 350 people.

Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

For Research Use Only. Not for use in diagnostic procedures.

Life Technologies Japan Contact

Eriko Takahata

+81 30 5566 6563

Eriko.Takahata@lifetech.com